HRP20200476T1 - Prognostički postupak i pribor koristan za navedeni postupak - Google Patents
Prognostički postupak i pribor koristan za navedeni postupak Download PDFInfo
- Publication number
- HRP20200476T1 HRP20200476T1 HRP20200476TT HRP20200476T HRP20200476T1 HR P20200476 T1 HRP20200476 T1 HR P20200476T1 HR P20200476T T HRP20200476T T HR P20200476TT HR P20200476 T HRP20200476 T HR P20200476T HR P20200476 T1 HRP20200476 T1 HR P20200476T1
- Authority
- HR
- Croatia
- Prior art keywords
- her2
- heteromer
- antibody
- level
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 12
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 2
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000000749 co-immunoprecipitation Methods 0.000 claims 1
- 230000008045 co-localization Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002165 resonance energy transfer Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
Claims (10)
1. Postupak predviđanja duljine lokalnog neometanog preživljavanja bolesti za pacijenta oboljelog od karcinima dojke, što uključuje: određivanje razine HER2/CB2 heteromerske ekspresije u biološkom uzorku dobivenog od navedenog pacijenta; uspoređivanje navedenog nivoa sa indikativnim standardima zdravih pojedinaca ili indikativnim za više ili niže opće preživljavanje; i time predviđanje duljine lokalnom bolešću neometanog preživljavanja povezanog s navedenom razinom ekspresije HER2/CB2 heteromera.
2. Postupak sukladno patentnom zahtjevu 1, pri čemu korak određivanja razine ekspresije HER2/CB2 heteromera uključuje korak dovođenja u kontakt pripravka za vezivanje HER2/CB2 heteromera.
3. Postupak sukladno patentnom zahtjevu 1 ili 2, pri čemu je korak određivanja razine HER2/CB2 heteromerske ekspresije odabran iz skupine koja uključuje protokole istovremene lokalizacije, test istovremene imunoprecipitacije, tehnike rezonantnog prijenosa energije, test ligacijske blizine i uporabu specifičnih sondi predviđenih za detekciju heteromera.
4. Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu korak određivanja razine HER2/CB2 heteromerske ekspresije je test ligacijske blizine (PLA) ili test bioluminiscentijskog rezonantnog prijenosa energije (BRET).
5. Postupak sukladno patentnom zahtjevu 2, pri čemu tvar vezivanja HER2/CB2 heteromera uključuje protutijelo koje se može specifično povezati s HER2/CB2 heteromerom.
6. Uporaba pribora u postupku sukladno bilo kojem od patentnih zahtjeva 1 do 5, navedeni pribor uključuje sredstvo koje može detektirati HER2/CB2 heteromer i instrukcije za uporabu.
7. Upotreba sukladno patentnom zahtjevu 6, pri čemu je navedeno sredstvo tvar vezivanja HER2/CB2 heteromera.
8. Upotreba sukladno patentnom zahtjevu 7, pri čemu navedena tvar vezivanja HER2/CB2 heteromera uključuje protutijelo koje se može specifično vezati na HER2/CB2 heteromer.
9. Uporaba sukladno patentnom zahtjevu 8, pri čemu je navedeno protutijelo poliklonalno protutijelo.
10. Uporaba sukladno patentnom zahtjevu 8, pri čemu je navedeno protutijelo monoklonalno protutijelo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016904288A AU2016904288A0 (en) | 2016-10-21 | Prognostic Method and Kits Useful in said Method | |
| EP17862681.8A EP3380843B1 (en) | 2016-10-21 | 2017-10-20 | Prognostic method and kits useful in said method |
| PCT/AU2017/051146 WO2018071986A1 (en) | 2016-10-21 | 2017-10-20 | Prognostic method and kits useful in said method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200476T1 true HRP20200476T1 (hr) | 2020-06-26 |
Family
ID=62018128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200476TT HRP20200476T1 (hr) | 2016-10-21 | 2020-03-23 | Prognostički postupak i pribor koristan za navedeni postupak |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10753935B2 (hr) |
| EP (1) | EP3380843B1 (hr) |
| JP (1) | JP6602481B2 (hr) |
| KR (2) | KR102008409B1 (hr) |
| CN (1) | CN110546510A (hr) |
| AU (1) | AU2017346940B2 (hr) |
| CA (1) | CA3009990A1 (hr) |
| HR (1) | HRP20200476T1 (hr) |
| IL (1) | IL260381A (hr) |
| NZ (1) | NZ743812A (hr) |
| RU (1) | RU2712225C2 (hr) |
| SG (1) | SG11201805478WA (hr) |
| WO (1) | WO2018071986A1 (hr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US6037134A (en) * | 1994-03-07 | 2000-03-14 | New York University Medical Center | Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes |
| SE516272C2 (sv) * | 2000-02-18 | 2001-12-10 | Ulf Landegren | Metoder och kit för analytdetektion mha proximitets-probning |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| GB201117956D0 (en) * | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
-
2017
- 2017-10-20 AU AU2017346940A patent/AU2017346940B2/en active Active
- 2017-10-20 CN CN201780079889.9A patent/CN110546510A/zh active Pending
- 2017-10-20 KR KR1020187019958A patent/KR102008409B1/ko active IP Right Grant
- 2017-10-20 SG SG11201805478WA patent/SG11201805478WA/en unknown
- 2017-10-20 RU RU2018126086A patent/RU2712225C2/ru active
- 2017-10-20 CA CA3009990A patent/CA3009990A1/en not_active Abandoned
- 2017-10-20 KR KR1020197017498A patent/KR20190073600A/ko active IP Right Grant
- 2017-10-20 EP EP17862681.8A patent/EP3380843B1/en active Active
- 2017-10-20 JP JP2018534649A patent/JP6602481B2/ja active Active
- 2017-10-20 WO PCT/AU2017/051146 patent/WO2018071986A1/en active Application Filing
- 2017-10-20 NZ NZ743812A patent/NZ743812A/en unknown
-
2018
- 2018-07-02 IL IL260381A patent/IL260381A/en unknown
- 2018-07-06 US US16/028,704 patent/US10753935B2/en active Active
-
2020
- 2020-03-23 HR HRP20200476TT patent/HRP20200476T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018126086A3 (hr) | 2020-01-16 |
| JP6602481B2 (ja) | 2019-11-06 |
| KR102008409B1 (ko) | 2019-08-07 |
| AU2017346940B2 (en) | 2018-08-23 |
| NZ743812A (en) | 2019-12-20 |
| EP3380843A4 (en) | 2018-10-03 |
| RU2712225C2 (ru) | 2020-01-27 |
| US10753935B2 (en) | 2020-08-25 |
| EP3380843A1 (en) | 2018-10-03 |
| KR20180099722A (ko) | 2018-09-05 |
| AU2017346940A1 (en) | 2018-07-12 |
| RU2018126086A (ru) | 2020-01-16 |
| WO2018071986A1 (en) | 2018-04-26 |
| US20180313840A1 (en) | 2018-11-01 |
| EP3380843B1 (en) | 2020-02-12 |
| IL260381A (en) | 2018-08-30 |
| CN110546510A (zh) | 2019-12-06 |
| KR20190073600A (ko) | 2019-06-26 |
| JP2019506601A (ja) | 2019-03-07 |
| SG11201805478WA (en) | 2018-07-30 |
| CA3009990A1 (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0707645B8 (pt) | métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano | |
| JP2019535015A5 (hr) | ||
| DK2073008T3 (da) | Forbedrede immunoassayfremgangsmåder | |
| WO2013132347A3 (en) | Improved elisa immunoassay for calprotectin | |
| TWI698639B (zh) | 前列腺抗原標準品及其用途 | |
| BR112016010106A2 (pt) | ensaios para igfbp7 com melhor desempenho em amostras biológicas | |
| CN101358976A (zh) | 检测六项肿瘤标志物的微阵列-酶联免疫检测试剂盒 | |
| NZ619883A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| BR112018005812A2 (pt) | ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico? | |
| JP2012509477A5 (hr) | ||
| BR112016002685A2 (pt) | ensaios para timp2 que apresentam melhor desempenho em amostras biológicas | |
| PH12020551371A1 (en) | Assays to detect neurodegeneration | |
| JP2014509515A5 (hr) | ||
| RU2019104870A (ru) | Комбинированный тест на наличие колоректального рака | |
| WO2010150254A3 (en) | A method and system for the detection of cancer | |
| JP2016536568A5 (hr) | ||
| JP2016519767A5 (hr) | ||
| WO2008063663A3 (en) | Poly (ethylene glycol) anti-body detection assays and kits for performing thereof | |
| RU2018123581A (ru) | Способ для выделения раковых стволовых клеток | |
| HRP20200476T1 (hr) | Prognostički postupak i pribor koristan za navedeni postupak | |
| CY1109461T1 (el) | Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου | |
| DE602005010548D1 (de) | Verbessertes verfahren zur diagnose des akuten koronarsyndroms | |
| NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2014159920A4 (en) | A device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers | |
| CN105974127A (zh) | 一种基于酶联免疫吸附技术的人中性粒细胞载脂蛋白异源二聚体定量装置 |